Field Trip Health (FTRP) Granted US Patent Covering Novel Psychedelic Molecule FT-104
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104
April 5, 2022 7:51 AM EDTTORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has granted the Company a patent for claims related to FT-104 (informally known as Isoprocin Glutarate), Field Trips first novel psychedelic molecule in development.
Claims in the patent application titled, Tryptamine Prodrugs, grant exclusive rights to Field Trip for the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines,... More
